Cresco Labs Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cresco Labs de 97.2% y 5.1% respectivamente, mientras que el BPA crecerá en un 98.1% al año.

Información clave

97.2%

Tasa de crecimiento de los beneficios

98.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	56.7%
Tasa de crecimiento de los ingresos	5.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	07 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Recent updates

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04

Cresco Labs Inc. (CSE:CL) Shares Could Be 41% Below Their Intrinsic Value Estimate

Oct 27

Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt

Oct 06

Cresco Labs Inc. (CSE:CL) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 27

Previsiones de crecimiento de beneficios e ingresos

CNSX:CL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	868	97	-2	26	2
12/31/2025	793	-39	36	51	9
12/31/2024	744	-30	30	69	13
12/31/2023	756	-176	1	59	N/A
9/30/2023	767	-339	-1	65	N/A
6/30/2023	786	-234	-23	50	N/A
3/31/2023	806	-211	-44	25	N/A
12/31/2022	825	-212	-67	19	N/A
9/30/2022	842	-65	-38	53	N/A
6/30/2022	848	-326	-62	34	N/A
3/31/2022	841	-318	-114	-2	N/A
12/31/2021	806	-320	-83	14	N/A
9/30/2021	750	-360	-99	-3	N/A
6/30/2021	687	-73	-74	20	N/A
3/31/2021	573	-105	-25	43	N/A
12/31/2020	463	-102	-97	-8	N/A
9/30/2020	345	-76	-149	-34	N/A
6/30/2020	231	-98	-186	-70	N/A
3/31/2020	168	-64	-185	-57	N/A
12/31/2019	124	-43	-121	-25	N/A
9/30/2019	101	-20	-94	-29	N/A
6/30/2019	78	-14	-67	-20	N/A
3/31/2019	57	-12	-53	-16	N/A
12/31/2018	41	-2	-40	-10	N/A
9/30/2018	28	0	-26	-4	N/A
6/30/2018	19	1	-23	-7	N/A
3/31/2018	13	1	-14	-6	N/A
12/31/2017	10	-3	-10	-5	N/A
12/31/2016	3	-8	N/A	-11	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CL sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2%).

Beneficios vs. Mercado: Se prevé que CL sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que CL sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (5.1% al año) de CL crezcan más despacio que el mercado de Canadian (6.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.1% al año) de CL crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CL se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Cresco Labs Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Forecast to breakeven in 2025

Consensus EPS estimates fall by 91%, revenue upgraded

No longer forecast to breakeven

Recent updates

Cresco Labs Inc., Annual General Meeting, Jun 10, 2024

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

New minor risk - Profitability

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Chief Financial Officer exercised options to buy CA$150k worth of stock.

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Cresco Labs Inc. Promotes Greg Butler to the Position of President

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

New minor risk - Shareholder dilution

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 91%, revenue upgraded

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)

Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023

New major risk - Share price stability

Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.

No longer forecast to breakeven

Is Cresco Labs (CSE:CL) Using Too Much Debt?

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 42%

Chief Financial Officer recently bought CA$149k worth of stock

Price target decreased by 8.4% to CA$4.80

Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023

Insufficient new directors

Consensus EPS estimates fall by 15%

Price target decreased by 36% to CA$3.82

First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)

Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023

Consensus EPS estimates fall by 40%

Insider recently sold CA$157k worth of stock

Consensus EPS estimates fall by 109%

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021)

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Now 22% undervalued after recent price drop

Co-Founder & Independent Director recently sold CA$1.7m worth of stock

Forecast breakeven date moved forward to 2023

Forecast breakeven date pushed back to 2024

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021)

Combs Enterprises signed a definitive agreements to acquire Certain New York, Illinois, and Massachusetts assets of Cresco Labs Inc. and Columbia Care Inc. for approximately $190 million.

Price target decreased to CA$10.10

Consensus forecasts updated

Cresco Labs Inc. to Report Q3, 2022 Results on Nov 15, 2022

Cresco Labs Inc. Announces Resignation of Sidney Dillard from the Board of Director

Aventine Property Group, Inc. acquired Cresco Labs Facility in Brookville, PA for $45 million

Consensus EPS estimates fall by 178%

We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Second quarter 2022 earnings: EPS exceeds analyst expectations

High number of new directors

Cresco Labs Inc. to Report Q2, 2022 Results on Aug 17, 2022

Forecast breakeven date moved forward to 2022

Co-Founder exercised options to buy CA$627k worth of stock.

Chief Financial Officer recently bought CA$104k worth of stock

Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

Price target decreased to CA$15.38

Forecast breakeven date pushed back to 2023

Cresco Labs Inc. to Report Q1, 2022 Results on May 18, 2022

High number of new directors

Cresco Labs Inc., Annual General Meeting, Jun 30, 2022

Price target decreased to CA$17.13